CASP3 and epilepsy: P38MAPK inhibitor SB203580 not only eliminates this potentiation [109], but also reduces phosphorylated p38 (p-p38) in the PTZ-triggered rat epilepsy model [110], resulting in a decrease in caspase 3 level (Fig. 2).